FVIIa antagonists

Details FVIIa antagonists FVIIa antagonists

2007-01-16

2007-01-16

Carlson, Karen Cochrane (Department: 1653)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Reexamination Certificate

active

10356257

ABSTRACT:
This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

REFERENCES:
patent: 3972859 (1976-08-01), Fujino et al.
patent: 4105603 (1978-08-01), Vale, Jr. et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5288931 (1994-02-01), Chang et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5583111 (1996-12-01), Hemberger et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5759954 (1998-06-01), Taguchi et al.
patent: 5834244 (1998-11-01), Dennis et al.
patent: 5843739 (1998-12-01), Slabas et al.
patent: 5863893 (1999-01-01), Dennis et al.
patent: 5880256 (1999-03-01), Dennis et al.
patent: 6087487 (2000-07-01), Vlasuk et al.
patent: 2004/0214272 (2004-10-01), La et al.
patent: 0 307 247 (1994-08-01), None
patent: 0 278 776 (1997-05-01), None
patent: WO 89/05859 (1989-06-01), None
patent: WO 90/01940 (1990-03-01), None
patent: WO 90/03390 (1990-04-01), None
patent: WO 91/11514 (1991-08-01), None
patent: WO 95/00541 (1995-01-01), None
patent: WO 96/40779 (1996-12-01), None
patent: WO 97/20939 (1997-06-01), None
patent: WO 00/04148 (2000-01-01), None
patent: WO 01/01749 (2001-01-01), None
patent: WO 01/10892 (2001-02-01), None
Abrahmsen, “Analysis of signals for secretion in the staphylococcal protein A”The EMBO Journal4:3901-3906 (1985).
Appleyard, R.K., “Segragation of new lysogenic types during growth of a doubly lysogenic strain derived fromEscherichia coliK12”Genetics39:440-452 (1954).
Badimon et al., “Hirudin and Other Thrombin Inhibitors: Experimental Results and Potential Clinical Applications”Trends Cardiovasc. Med.1(6) :261-267 (1991).
Banner et al., “The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor”Nature380:41-46 (1996).
Bone, R. C., “Modulators of Coagulation: A Critical Appraisal of Their Role In Sepsis”Arch Intern Med152:1381-1389 (1992).
Carson and Brozna, “The role of tissue factor in the production of thrombin”Blood. Coag. Fibrinol4:281-292 (1993).
Carter et al., “Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors”Nucl. Acids Res.13(12):4431-4443 (Jun. 25, 1986).
Carter, “American Chemical Society Symposium Series No. 427”Protein Purification: From Molecular Mechanisms to Large-Scale Processes., Ladisch et al., Eds., Chapter 13, pp. 181-193 (1990).
Castellanos-Serra ete al., “Expression and folding of an interleukin-2-proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the C-peptide and the N-terminal fused sequence”FEBS Letters378:171-176 (1996).
Clackson et al., “In vitro selection from protein and peptide libraries”Trends Biotechnol.12:173-184 (1994).
Colman, R. W., “The Role of Plasma Proteases In Septic Shock”The New England J. of Med.320(18):1207-1209 (1989).
Creasey et al., “Tissue Factor Pathway Inhibitor Reduces Mortality fromEscherichia coliSeptic Shock”J. Clin. Invest.91:2850-2860 (1993).
Cunningham and Wells, “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”Science244:1081-1085 (1989).
Davie et al., “The Coagulation Cascade: Initiation, Maintenance, and Regulation”Biochemistry30(43):10363-10370 (1991).
Davie, E.W., “Biochemical and Molecular Aspects of the Coagulation Cascade”Thrombosis and Haemmostasis74:1-6 (1995).
Dennis et al., “Binding interactions of kistrin with platelet glycoprotein IIb-IIIa: analysis by site-directed mutagenesis”Proteins: Structure, Function, and Genetics15(3):312-321 (1993).
Dennis et al., “Peptide Exosite Inhibitors of Factor VIIa as Anticoagulants.”Nature404:465-470 (Mar. 2000).
Dennis et al., “Selection and Characterization of a New Class of Peptide Exosite Inhibitors of Coagulation Factor VIIa.”Biochemistry40:9513-9521 (2001).
Dickinson et al., “Influence of Cofactor Binding and Active Site Occupancy on the Conformation of the Macromolecular Substrate Exosite of Factor VIIa”J. Mol. Biol. 277:959-971 (1998).
Edgington, T.S. et al., “The Structural Basis of Function of the TFVIIa Complex in the Cellular Initiation of Coagulation”Thrombosis and Haemostasis78:401-405 (1997).
Eigenbrot, C. et al., “The Factor VII Zymogen Structure Reveals Reregistration of B Strands during Activation”Structure9:627-636 (2001).
Engels et al., “Gene Synthesis”Agnew. Chem. Int. Ed. Engl.28:716-734 (1989).
Ganong, “Regulation of Gastrointestinal Function”Review of Medical Physiology, Lange, 13 edition, Los Altos, California, Chapter 26, pp. 411-414 (1987).
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5”J. Gen Virol.36:59-72 (1977).
Greene, “Protection for the Amino Group”Protective Groups in Organic Synthesis, 2nd edition, New York:John Wiley & sons pp. 309-405 (1991).
Harris, J.L., “Definition and Redesign of the Extended Substrate Specificity of Granzyme B”Journal of Biological Chemistry273:27364-27373 (1998).
Haskel et al., “Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein-Associated Coagulation Inhibitor”Circulation84(2);821-827 (1991).
Holst et al., “Antithrombotic Properties of a Truncated Recombinant Tissue Factor Pathway Inhibitor in an Experimental Venous Thrombosis Model”Haemostasis23 (Suppl. 1):112-117 (1993).
Houghten., “General Method for the Rapid Solid-Phase Synthesis of Large Numbers of Peptides: Specificity of Antigen-Antibody Interaction at the Level of Individual Amino Acids.”Proc. Natl. Acad. Sci. USA82:5131-5135 (Aug. 1985).
Hsiao et al., “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene”Proc. Natl. Acad. Sci. USA76:3829-3833 (1979).
Husbyn et al., “Peptides corresponding to the second epidermal growth factor-like domain of human blood coagulation factor VII: synthesis, folding and biological activity”J. Peptide Res.50:475-482 (1997).
Ke, S.H., “Optimal Subsite Occupancy and Design of a Selective Inhibitor of Urokinase”Journal of Biological Chemistry272:20456-20462 (1997).
Kelley et al., “A Soluble Tissue Factor Mutant Is a Selective Anticoagulant and Antithrombotic Agent”Blood89(9):3219-3227 (1997).
Kelley, R.F., “Folding of Eukaryotic Proteins Produced inEscherichia Coli ” Genetic Engineering Principles and Methods, Setlow, J.M., New York, New York:Plenum Press vol. 12:1-19 (1990).
Kelly et al., “Ca2+Binding to the First Epidermal Growth Factor Module Coagulation Factor VIIa Is Important for Cofactor Interaction and Proteolytic Function”Journal of Biological Chemistry272:17467-17472 (1997).
Kridel, S. J., “A Substrate Phage Enzyme-Linked Immunosorbent Assay to Profile Panels of Proteases”Analytical Biochemistry294:176-184 (2001).
Kunkel et al., “Efficient site-directed mutagenesis using uracil-containing DNA”Methods in Enzymology204:125-139 (1991).
Kunkel et al., “Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection”Methods in Enzymology154:367-382 (1987).
Lee et al., “Potent Bifunctional Anticoagulants: Kunitz Domain-Tissue Factor Fusion Proteins”Biochemistry36(19):5607-5611 (1997).
Lehninger, A.L., “The amino acid building blocks of protein”Biochemistry, 2nd edition, New York, Ne

Affiliated with

Also associated with

Rating

FVIIa antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FVIIa antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FVIIa antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3725764